Dual-tracer PET scan for cancer and brain conditions
Part of Brain & nervous system, Cancer, Kidney & urinary clinical trials.
This study tests a new PET imaging method that uses two tracers at once to better see tumors in prostate cancer, neuroendocrine tumors, gliomas, and to help diagnose Parkinson's syndrome. It may help doctors find disease more accurately.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have one of the following: prostate cancer, neuroendocrine tumor, glioma, or suspected Parkinson's syndrome.
- For healthy volunteers: you have a body mass index (BMI) between 19 and 26.
- You can tolerate an IV injection and are not allergic to alcohol.
- You are not pregnant or breastfeeding, and you have no serious heart, kidney, lung, or mental health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging method (PET scan) that uses a special tracer to find prostate cancer cells, whether it's the first diagnosis or a recurrence after treatment. The goal is to see how well this imaging works for locating cancer in the body.
This study tests a new type of PET/CT scan that uses a special tracer (68Ga-MY6349) to better see prostate cancer in the body. It may help doctors find cancer that has come back or spread, so you can get the right treatment sooner.
This study tests a new way to take brain imaging scans (PET scans) using a very small amount of radioactive tracer. Researchers want to see if they can get clear pictures of your brain while reducing your radiation exposure compared to standard scans.
This early-phase study tests special PET/CT scans using a radioactive tracer to see cancer areas that have specific targets. It may help doctors better visualize tumors and plan next steps, using scans that you may already be familiar with (FDG) plus targeted tracers.
This study does two PET/CT scans instead of one to test a new imaging technology from GE. It may help improve how doctors see disease.
This study tests a new imaging agent (68Ga-NYM032) used with PET/CT scans to help doctors better detect prostate cancer before surgery. If you have biopsy-confirmed prostate cancer and are planning to have your prostate removed, this trial may help evaluate whether this new imaging method improves cancer detection.
Hear when a new Prostatic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.